Armata Pharmaceuticals In... (ARMP)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 1.94 |
Market Cap | 74.90M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -1.15 |
PE Ratio (ttm) | -1.8 |
Forward PE | n/a |
Analyst | Buy |
Ask | 3.31 |
Volume | 3,863 |
Avg. Volume (20D) | 11,458 |
Open | 2.07 |
Previous Close | 2.08 |
Day's Range | 2.01 - 2.22 |
52-Week Range | 1.80 - 4.48 |
Beta | undefined |
About ARMP
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It h...
Analyst Forecast
According to 1 analyst ratings, the average rating for ARMP stock is "Buy." The 12-month stock price forecast is $7, which is an increase of 238.16% from the latest price.
Next Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription